NCT06323239View on ClinicalTrials.gov

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions
Nasopharyngeal Carcinoma
Interventions
RADIATION

SBRT

SBRT for metastatic lesions

RADIATION

Low-dose Radiotherapy (LDRT)

LDRT for metastatic lesions

DRUG

Toripalimab

6 cycles for combined therapy. Toripalimab maintenance for 1 year.

DRUG

Gemcitabine

6 cycles for combined therapy.

DRUG

Cisplatin

6 cycles for combined therapy.

RADIATION

IMRT

IMRT for primary lesion

Trial Locations (1)

Unknown

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER